Crossmark

Genome-wide analysis of insomnia disorder

Crossref DOI link: https://doi.org/10.1038/s41380-018-0033-5

Published Online: 2018-03-08

Published Print: 2018-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Stein, Murray B. https://orcid.org/0000-0001-9564-2871
McCarthy, Michael J. https://orcid.org/0000-0001-6219-4945
Chen, Chia-Yen https://orcid.org/0000-0001-9548-5597
Jain, Sonia

Gelernter, Joel https://orcid.org/0000-0002-4067-1859
He, Feng

Heeringa, Steven G.

Kessler, Ronald C.

Nock, Matthew K.

Ripke, Stephan

Sun, Xiaoying

Wynn, Gary H.

Smoller, Jordan W.

Ursano, Robert J.
License Information

Text and Data Mining valid from 2018-03-08
More Information

Article History

Received: 14 April 2017

Revised: 18 December 2017

Accepted: 15 January 2018

First Online: 8 March 2018

Compliance with ethical standards

:

: Dr. M.B.S. has in the past three years been a consultant for Actelion, Aptinyx, Dart Neuroscience, Healthcare Management Technologies, Janssen, Neurocrine Biosciences, Oxeia Biopharmaceuticals, Pfizer, and Resilience Therapeutics. Dr. M.B.S. owns founders shares and stock options in Resilience Therapeutics and has stock options in Oxeia Biopharmaceticals. Dr. J.W.S. is an unpaid member of the Scientific Advisory Board of PsyBrain, Inc. In the past 3 years, Dr. R.C.K. has been a consultant for Hoffman-La Roche, Inc., Johnson & Johnson Wellness and Prevention, and Sanofi-Aventis Groupe. Dr. R.C.K. has served on advisory boards for Mensante Corporation, Plus One Health Management, Lake Nona Institute, and US Preventive Medicine. Dr. R.C.K. owns 25% share in DataStat, Inc. The remaining authors declare that they have no conflict of interest.